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Background: Advances in treatment have increased childhood cancer 5-year survival rates to greater than 80%.
However, children previously treated with radiation are at significantly increased risk of developing subsequent neoplasms,
the most common of which are skin cancers. The National Cancer Institute and Children’s Oncology Group have issued
recommendations for survivors treated with radiation to perform monthly skin self-examinations and receive a physician
skin examination at least annually, as early detection has demonstrated markedly improved outcomes in the diagnosis
and treatment of skin cancers. The goal of the present study is to increase rates of skin self-examinations and clinical skin
examinations among adult survivors of childhood cancer treated with radiation.
Methods/Design: This randomized controlled trial uses a 3-group comparative effectiveness design comparing: (1) Patient
Activation and Education (PAE) including text messaging, print and web-based tutorials over 12 months; (2) PAE plus
physician activation (PAE +MD) adding physician activation/educational materials about survivors’ increased skin cancer
risk and conducting full-body skin exams; and (3) PAE plus physician activation, plus teledermoscopy (PAE +MD+ TD)
adding participant receipt of a dermatoscope intended to empower them to photograph suspect moles or lesions for
review by the study dermatologist.
Discussion: The current study addresses barriers to screening in this population by providing educational and motivational
information for both survivors and physicians regarding the value of periodic skin examinations. It also utilizes innovative
mobile health technology to encourage and motivate (that is activate) survivors to conduct skin self-examinations, request
physician exams, and obtain treatment when worrisome lesions are found. Finally, as a comparative effectiveness trial, this
study isolates the effects of adding specific components to the patient activation intervention to test the most effective
intervention for enhancing skin examination vigilance among this high-risk group.
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Advances in diagnosis and treatment for children with
cancer have contributed to an overall 5-year survival rate
that currently exceeds 80% [1]. There are over 420,000
estimated survivors of childhood cancer in the United
States [2]. In a study of 1,713 childhood cancer survivors
using clinical evaluations, Hudson et al. found that 95% of
these individuals experienced at least 1 chronic health
condition by age 45 [3,4]. The late effects of the treatment
of childhood cancer includes impaired growth and devel-
opment, decreased or loss of fertility, organ dysfunction,
cognitive impairment [2,5,6], and second neoplasms which
occur in an estimated 20.5% of these individuals [7-11].
Among survivors receiving radiation treatment, the
relative risk of developing a subsequent neoplasm is 2.7
(CI = 2.2 to 3.3). These neoplasms most frequently
occur within the radiation field [8].
Skin cancers, primarily basal cell carcinomas (BCCs),
are the most common subsequent neoplasm faced by
childhood cancer survivors [8,12,13]. Approximately
20 years after receiving radiation therapy, when most of
these patients are in their 30s, this population faces the
prospect of multiple and recurrent skin cancers at rates
much greater than that of an age-matched general popu-
lation [8,12-14]. Adult survivors of childhood cancer
under 35 who were treated with radiation have nearly a
40-fold risk for non-melanoma skin cancer and more
than 2.5 times the risk of melanoma compared with the
general population [13,15,16]. Delay of identification and
diagnosis of skin cancer can result in unnecessary morbid-
ity [17]. Most recent evidence indicates that earlier diag-
nosis of a BCC can lead to smaller tumors, potentially less
extensive treatment, better outcomes, and lower treatment
costs [18].
Because of the extraordinarily high skin cancer rates in
this special population, in April 2012 (updated in April
2014), the National Cancer Institute released a PDQ® (evi-
dence-based data summary) strongly encouraging the use
of the annual dermatological exam to screen for early-
onset skin cancer in childhood cancer survivors [19]. The
Children’s Oncology Group also specifies in its long-term
survivorship guidelines that survivors of childhood cancer
who received radiation should check their skin monthly
for changes and have a thorough skin examination by a
health care provider at least once a year [20].
Importance of early detection
Skin cancer and its precursors ‘writes their message in
the skin for all of us to see’ and can be easily seen by the
patient, their providers, and significant others [21-25].
Therefore, teaching skin self-examination and encour-
aging patients to alert their physicians to skin changes
provides a key opportunity for education and early detec-
tion. In the general population, thorough skin self-examination (TSSE), although only practiced by 15% of
subjects, reduced mortality due to melanoma by an esti-
mated 60% in one major case-control study [26]. Physician
diagnosis was associated with a markedly higher rate of
thinner melanoma in Australia [27], and a nearly 50% re-
duction in melanoma mortality in a region in Germany
compared with unscreened control populations from adja-
cent regions in Germany and all of Denmark [28].
The American Academy of Dermatology has recom-
mended the practice of skin self-examination to detect
new and or changing lesions [29]. Individuals are en-
couraged to perform skin self-examinations regularly
(for example, monthly) using the ABCDE (Asymmetry,
Border, Color, Diameter, Evolution) algorithm [30]. Indi-
viduals should also request periodic full-body skin exam-
inations as a national study of physicians indicate that
they are more inclined to screen when requested to do
so by their patients [31]. Such practices are particularly
meaningful for those at highest risk for skin cancer, such
as individuals treated with radiation during childhood.
However, previous studies have demonstrated that only
29% of survivors report that they have ever received a
physician skin examination for cancer [32].
Methods/Design
Study objectives and specific aims
The objective of this randomized study, entitled Advancing
Survivors’ Knowledge (ASK) About Skin Cancer, is to de-
termine the impact of a 12-month Patient Activation and
Education intervention focused on early detection of skin
cancer and timely medical follow-up among childhood
cancer survivors treated with radiation. Key components of
the ASK intervention utilize innovative technologies to ac-
tivate patients to conduct skin self-examinations, request
physician exams, and obtain treatment when worrisome le-
sions are found.
The specific aims of this study are: (1) to determine the
impact of a Patient Activation and Education (PAE) inter-
vention with and without physician activation (PAE +MD)
and teledermoscopy (PAE +MD+TD) on skin cancer
early detection practices measured at 12 and 18 months;
(2) to determine the impact of the intervention on time to
diagnosis; and (3) to estimate the cost and cost-
effectiveness of the intervention. The intervention will
teach skin cancer early detection skills to survivors, con-
nect them with health care resources, and prompt medical
staff who see this population to perform clinical skin
exams.
Study participants
The study will be conducted using the cohort of the
Childhood Cancer Survivor Study (CCSS), funded by
NCI grant U24 CA55727 (Principal Investigator, GT
Armstrong). This cohort includes participants from 50
states diagnosed with a childhood cancer between 1970
and 1986 before age 21 years. Participants have been re-
cruited by 27 clinical sites in the United States (US) and
Canada. As of 2007, there were 12,323 known living par-
ticipants, 46% of the sample were female, median age
was 36 years, 73% were under age 40 years, 88% were
White, non-Hispanic, and 25% had at least a college
education [33-35].
Eligibility criteria for the ASK study include: (1)
current age of 18 years or older; (2) previously treated
with radiation for childhood cancer; (3) having seen their
primary care physician or oncologist in the previous
2 years or planning to do so in the next year; (4) having
no personal history of a skin cancer diagnosis, (5) pos-
session of a cellular phone that can receive text mes-
sages, and (6) access to a DermLite (3Gen, San Juan
Capistrano, CA, USA) compatible smartphone or tablet.
Informed consent will be obtained from each enrolled
participant in the ASK study.
Conceptual model
The ASK study is guided by the 13-item Patient Activation
Measure (PAM) [36], which posits that activated patients
are better prepared to participate in self-management ac-
tivities. Patient activation is increasingly seen as central to
achieving improvements in the quality of care, better
health outcomes, and less costly health care service
utilization. Activation involves 4 stages: (1) believing that
taking an active role as a patient is important, (2) having
the confidence and knowledge necessary to take action,
(3) actually taking action to maintain and improve one’s
health, and (4) staying the course even under stress [36].
Individuals with higher levels of patient activation are
more likely to engage in preventive behaviors such as at-
tending routine check-ups and undergoing screening [37].
Utilizing key aspects of the PAM framework, the ASK
study intervention was developed to emphasize the im-
portance of understanding one’s role in managing his/her
health and having the knowledge, skills, and confidence to
do so.
Since 2004, numerous cross-sectional studies and ran-
domized controlled trials have found patient activation
to be related to healthy behaviors, appropriate use of the
health care system, consumer behaviors (for example,
researching physician qualifications, preparing a list of
questions for a doctor visit), and chronic care self-
management [38-41]. In an intervention trial of chronic
disease patients, Hibbard and colleagues found positive
change in activation resulted in positive change in vari-
ous self-management behaviors [42]. Similarly, in a web-
based randomized controlled trial for adults with
asthma, hypertension, or diabetes, Solomon and col-
leagues determined that an online intervention had both
positive and significant effects on the patient activationlevels of participants in the intervention group (specific-
ally attitudes toward knowledge, skills, and confidence in
self-managing health), noting their increased likelihood
to adhere to recommended health care practices [43].
Evidence suggests that primary care providers can play
an important role in increasing patient activation
[38,44]. For example, one study found that patients who
report that their provider helped them learn to monitor
their condition, set goals, and/or set up an exercise pro-
gram, were more activated than patients who did not
have this experience [38]. In addition to patient activa-
tion, the ASK study includes a primary care activation
component described below.
Design overview
This randomized controlled trial uses a three-group
comparative effectiveness design comparing (Figure 1):
 Patient Activation and Education (PAE), including
text messaging, web-based educational content, and
print resources;
 PAE plus physician activation (PAE +MD): adding
physician activation/educational materials (web and
print) targeted to identified primary care providers;
 PAE plus physician activation, plus teledermoscopy
(PAE +MD + TD): adding participant receipt of a
dermatoscope and instructions for use.
Teledermoscopy is a potentially valuable resource
that may reduce costs and increase efficiency for
both patients and physicians by providing expert
skin assessments remotely [45].
Primary study outcomes
Primary study outcomes will be measured at baseline,
12- and 18-months and include the following: (1) at least
1 thorough skin self-examination completed by the pa-
tient in the 2 months prior to both the 12- and 18-
month survey; (2) at least 1 physician skin examination
prior to 18-month survey; and, (3) reduction of the time




Participants of the CCSS cohort who received radiation
for their childhood cancer and were not known to have
a personal history of skin cancer are eligible to partici-
pate. Recruitment for the current intervention coincided
with the release of the CCSS Follow-Up 5 (FU5) survey;
therefore, FU5 is utilized as a recruitment screening tool.
Individuals who fulfill the criteria listed above are sent
the screening questions: (1) Have you been diagnosed
with a skin cancer; (2) Have you seen a regular health
care provider in the past 2 years, or do you plan to see
Figure 1 Study design overview for the three intervention arms.
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that can receive text messages; and, (4) Do you have ac-
cess to a smartphone or tablet? Participants are eligible
to participate in the ASK study if they answer ‘no’ to the
first question and ‘yes’ to the remaining questions.
Recruitment
The study protocol was reviewed and approved by the
Institutional Review Board of Harvard TH Chan School
of Public Health (approval number: IRB12-0002). Partici-
pants who meet study eligibility criteria will be invited
to enroll. The invitation packet includes the invitation
letter, Health Insurance Portability and Accountability
Act (HIPAA) authorization, consent form, and the base-
line survey.
Upon receipt of the completed survey and HIPAA
authorization, the participant is officially enrolled in the
study and randomized to one of three study arms. Within
7 days of randomization, each participant receives an en-
rollment packet that includes: a letter welcoming them to
the study; print materials about their skin cancer risk, how
to conduct skin self-examinations, an appointment check-
list providing tips and suggestions about physician skin ex-
aminations for participants to reference when they go to
see their doctor; and details about how to access the study
website. Participants in Arm 3 also receive the dermato-
scope and instructions for attaching it to their smartphone,
using it, and uploading photos to the photo repository.
Intervention components
The key intervention components are summarized in
Table 1. The content of developed materials was partially
influenced by Key Informant Interviews (n = 6, 50% female)
conducted with members of the study cohort from whichparticipants are being recruited. Common themes from
these interviews regarding skin cancer knowledge and
screening practices, attitudes about survivor status,
preferences for receiving health information, and Inter-
net and mobile phone connectivity and use were foun-
dational in designing the communication strategy that
guided development of the study’s name, logo, website,
and print materials. A key development in the function-
ality and user-friendliness of the intervention is the
added development of a specially designed mobile inter-
face of the study website for convenient and functional
access on mobile devices such as mobile phones and
tablets. Provider intervention materials were guided by
discussions with both primary care physicians and phys-
ician specialists. The study name/logo, website, educational
print materials, and image repository were developed by
the Health Communication Core of Dana-Farber Cancer
Institute (www.healthcommcore.org) in collaboration with
study staff.
Arm 1: Patient Activation and Education
All participants receive educational print materials; ac-
cess via individual login to the study website, which pro-
vides additional information, videos, and images of
abnormal lesions; text messages designed to prompt use
of the website and the target behaviors; and study staff
contact information. After receipt of the introductory
materials packet, participants are encouraged to use the
study website for education about typical and atypical le-
sions, and then to examine themselves for any lesions of
concern. It is anticipated that employment of the PAM
will guide participants toward increased awareness of
their risk of skin cancer while positively encouraging
them to engage in recommended screening behaviors.
Table 1 Core intervention components of the three arms
Intervention
strategy
Content Mediating variables addressed
PAE • 14 text
messages
• 1 text: welcoming participants to the study • PAM components:
• 12 texts: reminders to conduct thorough skin self-
examinations (TSSE), prompts to see a health care provider
(HCP) for suspect lesions, messages highlighting key areas on
targeting mediators and suggesting relevant website content
(for example, demo of TSSE, risk factors for skin cancer)
Playing an active role in early detection
• 1 text: reminding participants about the 18-month
survey




• Information about skin cancer risk among survivors, and




• Risk perception: re cancer status• Information about how to conduct a self-examination
and clinical images illustrating what to look for
• Information about how to ask a HCP for a skin exam: • Barrier reduction
Printable checklist
Guide to discussion
• Information about preventive behaviors
• Interactive skin exam quizzes
• Tips for making ED a priority
• Lay summaries of research on the efficacy of skin exams







• Introduction letter describing intervention and encouraging
MDs to do a full-body skin examination at the patient’s
next visit
• Self-efficacy to perform a skin examination on
the patient
• Guide to conducting a full skin cancer examination
• Information about survivors’ increased risk of skin cancer
• Access to the provider section of the ASK website,
which houses additional resources including clinical
images illustrating what to look for
• Study
website
• Information about skin cancer risk among survivors, and
the key roles that skin exams and early detection (ED) play
• Barrier reduction related to HCP provision of
skin examination (for example, how to do exam;
how to identify suspicious lesions)
• Video demonstration of how to conduct a thorough
clinical skin examination
• Summaries of research on the efficacy of skin exams
• Videos and links to additional resources regarding skin cancer
• Access to all participant website materials
PAE +MD + TD • Telederm • Participant given dermatoscope attachment • Barrier reduction decrease wait times for dermatology
review of lesions
• Website provides information about typical and atypical
lesions
• As part of regular TSSE, participant takes photographs
of suspect lesions and sends to study dermatologist
• Teledermoscopy report sent within 1 week, includes
instructions to health care provider about needed follow-up
or treatment
Abbreviations: PAE, Patient Activation and Education, PAE +MD, PAE plus physician activation; PAE +MD + TD, PAE plus physician activation, plus teledermoscopy,
PAM, Patient Activation Measure.Participants receive 14 separate text messages (Table 2
for examples) throughout the 18-month period designed
to encourage them to: (1) carefully examine their skin
for cancer with the aid of the study’s tools, such as pic-
torial diagrams and photographs of abnormal lesions forreference; (2) discuss concerns with and request skin
exams from their physicians utilizing a checklist that
they can print to bring to their physician visit or access
on the mobile study site during their appointment; and,
(3) develop a collaborative care plan (between the
Table 2 Select text messages sent to participants over the 12-month study and follow-up period
Type of message Message content
Early detection
Physician exam
ASK! Your past radiation treatment increases your skin cancer risk. Checking your skin monthly and asking for a Dr.’s exam
are vital to catch & treat it early.
Early detection
Physician exam
ASK! Your doctor is more likely to examine your skin if they know of your skin cancer risk. Here’s how to ask for an exam &
an appt checklist: bit.ly/
Early detection
Physician exam
ASK! If your doctor refers you to a dermatologist or other doctor for a mole or area of concern on your skin, follow-up right
away! Here’s why: bit.ly/
Early detection
Website/Educational
The ABCDE rule will help you find unusual moles during your monthly skin self-check. More on the ABCDE rule & pictures
plus watch a video: bit.ly/
Early detection
Educational
ASK! Melanoma, the most serious form of skin cancer, “writes its message in the skin for all to see”. Check yourself regularly
for anything unusual & follow up!
Early detection
Website
Thanks for being a part of ASK! Do a total skin check monthly–carefully looking at your skin from head to toe and front to
back. Here’s how: bit.ly/
Early detection
Website/Educational
ASK! Skin cancer can grow from existing moles and damaged skin. Get to know your skin. Check for any changes. You’ll get
better each time. Tips: bit.ly/
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bility for monitoring and quickly following up on new
and changing moles and lesions.
Arm 2: Patient Activation and Education plus physician activation
In addition to the PAE elements, participants’ physicians
are mailed physician activation materials. The goal of the
physician activation intervention is to increase provider
knowledge about the importance of early detection for sur-
vivors, with a particular focus on this specific population,
motivate these providers to educate and screen patients,
and to provide them with the skills and confidence needed
to perform clinical examinations. Provider intervention
materials include: (1) an introduction letter describing the
intervention and examination recommendations; (2) infor-
mation about increased risk of skin cancer for adult survi-
vors treated with radiation and the role of primary care in
early detection and treatment; (3) instructions on how to
conduct a full skin cancer examination; and, (4) access to
the study website, with specific information for health care
professionals that contains resources and images to assist
in conducting skin exams and identifying potential skin
cancers. Providers are also given access to the new web-
based curriculum guide developed by the INFORMED
study of skin screening for primary care physicians [46,47].
Physicians are provided with a study 1-800 number should
they have questions regarding the examination or follow-up
care or need help ensuring an expedited referral to a derma-
tologist from the American Academy of Dermatology.
Arm 3: Patient Activation and Education plus physician
activation and teledermoscopy
In addition to PAE +MD, Arm 3 participants receive a
dermatoscope that permits acquisition of dermoscopic
images through the participant’s smartphone camera and
instructional materials for use of this attachment includ-
ing a customized instructional video. Participants can
take high-resolution photographs of suspect moles orlesions and upload these photos via a secure web portal
for review by the study dermatologist. Participants are
instructed to ask significant others to take photographs
of back-of-body lesions. A letter with the results of the
assessment of submitted photographs to the study website
will be sent to the participant’s identified physician encour-
aging the physicians to emphasize the importance of
monthly self-examinations and encouraging referral to a
dermatologist for a clinical examination, if necessary. Partic-
ipants are informed that they must contact their physicians
to receive dermoscopy reports. Participants have access to
teledermoscopy for 12 months after enrollment.
The study staff, in cooperation with 3Gen, the manu-
facturer of the DermLite, developed written and video
instructional materials to assist participants in effectively
using the DermLite attachment and ensuring proper up-
load of photographs taken to be reviewed by the study
dermatologist. The DermLite (Figure 2) is a portable
dermatoscope that can be attached to smartphones and
tablets and is primarily used for the examination of sus-
picious skin lesions. It consists of a magnification lens
and light-emitting diode (LED) lighting that allows high-
quality visualization of subsurface skin structures that
are not typically visible to the naked eye. Advantages of
this technology are that it can facilitate detection of skin
cancers in the early stages of development and offers the
possibility of increased convenience for both physicians
and patients as it has the potential to be performed by the
patient and sent remotely to a physician specialist. Print
and online materials provided for Arm 3 participants in-
clude step-by-step instructions regarding the use of the
DermLite, troubleshooting tips, and detailed instructions
about uploading photos via the study website.
Another key element of the study is the development
of the photo repository where participants in the PAE +
MD +TD arm will upload DermLite photographs for re-
view. Images can be uploaded from participants’ phones/
tablets or the study website. When participants upload a
Figure 2 DermLite lens attachment by 3Gen.photograph to the repository, they are asked a series of
questions including: (1) date the photo was taken, (2) if
they had previously submitted a photo of that particular
mole, mark or spot, (3) location of the mole, mark, or
spot (with a drop down menu of options to select from),
and, (4) symptoms of the mole, mark or spot (with a drop
down menu of options to select from). The photos will be
reviewed by study staff to ensure acceptable quality and con-
tent before they are sent to the study dermatologist. The
photographs will be reviewed by the study dermatologist
and an individualized report and status will be generated for
each photograph (for example, (a) morphology is suggestive
of a benign lesion; (b) morphology is indeterminate and
management will require evaluation and follow-up with a
physician; (c) lesion has morphologic features suggestive of
malignancy; and, (d) image is of insufficient quality - photo-
graph needs to be retaken). The report will be sent to the
corresponding participant’s physician. The participant will
be instructed to contact his or her identified physician to
receive the teledermoscopy report and to discuss follow-up
measures.
Tracking and follow-up
All participants will utilize a unique username and pass-
word to access the website. We are able to collect data
on participants’ paths through the site, the amount of
time spent on each page, total session time, and use of
various components. Analytic software will be used to
track aggregate website statistics. Participants will also
be asked on the 12- and 18-month surveys to report
their use of and experiences with the website. Study staff
will utilize the photo repository database to track the
number of photographs sent per participant as well as
the time interval from the date the photograph was sent
to the date that a report was processed. Additionally, on
the 12- and 18-month surveys, participants will be asked
if they brought the appointment checklist to their phys-
ician visits and the frequency with which they examinedtheir skin, but found lesions of little concern, and chose
not to use teledermoscopy (PAE +MD + TD arm only).Outcomes and measurements
Thorough skin self-examination (TSSE)
Self-report of TSSE has been validated [22,48], and as an
outcome will be defined as performing at least one TSSE
during the 2 months prior to the 12- and 18-month
follow-up assessments. Participants will be asked how
often in the prior 2 months they had performed a TSSE
and if, in the 2 months prior to survey completion, they
carefully examined each of 9 areas of the body (‘the front
of your body from the waist up’, ‘the front of your thighs
and legs’, ‘the bottom of your feet’, ‘your calves’, ‘the backs
of your thighs’, ‘your buttocks’, ‘the lower parts of your
back’, ‘your upper back’, and ‘your scalp’) [22,48]. Those
who respond ‘yes’ to each of these nine questions will be
considered to have performed TSSE.Physician skin cancer examination
Completion of a physician skin exam will be assessed at
baseline, 12 months, and 18 months by participant re-
port and chart review. At each assessment time point,
participants will be asked: ‘During the past 12 months,
has your regular health care provider or your dermatolo-
gist carefully examined your whole body for any sign of
skin cancer’, and whether the examination took place
during a routinely scheduled visit or was prompted by a
request from the participant. Participants’ self-report will
be corroborated via chart review using a standard form
submitted to the provider to assess each of the following:
a skin examination has been performed, a skin self-exam
has been recommended, and completion of a follow-up
visit and the date for such a visit has been reported.
Physician offices will be incentivized a total of $25.00 for
review of the participant’s medical record related to the
skin exam to be completed after the participant com-
pletes his/her 18-month survey.Reduced time interval
We used the following assumptions from the literature:
mean wait time (time between call for appointment and
actual appointment) of 38.2 days (95% CI = (35.4, 41.0)
[49]. Based on the proportion of individuals with atypical
moles and changing moles, we assume that for each of
the study groups, there will be an estimated 60 to 75
participants per 267 in each group who will seek care
from their primary physician or dermatologist in the 18-
month period for a suspect skin lesion. A clinically sig-
nificant improvement in reduction of time between the
first finding of a suspect lesion and diagnostic visit
would be between 14 and 21 days.
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We will also examine the impact of the intervention on
key mediating variables hypothesized to be related to be-
havior change, including: risk perception related to one’s
prior cancer status and risk of skin cancer, self-efficacy to
perform a TSSE and to ask a physician to perform a
complete skin examination, barriers (such as not knowing
what types of moles or lesions to look for), demographics,
skin cancer risk factors, skin cancer knowledge, attitudes
toward TSSE, and detection awareness of basic warning
signs of melanoma and BCCs [48,50-52]. In addition, we
will test for interactions between these variables and the
PAM, looking at subscales for risk perception, self-
efficacy, barriers, and awareness [53].
Economic impact measures
To estimate the economic impact of the intervention, at
each assessment, we will examine participants’ visits
with primary care providers and dermatologists, diag-
nostic procedures including biopsies and imaging, and
treatment for newly-diagnosed skin conditions. This self-
reported information will be verified and supplemented by
data collected in chart reviews. We will use Medicare’s
Direct Practice Expense and Resource Based Relative
Value Scale (RBRVS) to estimate average unit costs for
physician and laboratory services. A range of unit cost es-
timates will be evaluated in sensitivity analysis.
Our assessment of the downstream costs of the inter-
vention, as well as the cost of the intervention itself, will
allow performance of a limited cost-effectiveness analysis.
We will estimate the cost per additional full-body skin
cancer exam completed and the cost per additional skin
cancer case detected, comparing the three intervention
arms. The economic impact of the intervention will be
evaluated using standard incremental cost-effectiveness
analysis methods, and sensitivity analysis will be used to
assess the impact of assumptions and uncertainty on re-
sults and conclusions [54,55].
Power calculations
Sample size considerations are based on an equal alloca-
tion of participants to intervention arms. Our primary
outcome focuses on increases in both physician screening
and skin self-examination; the prevalence of screening and
expected effect sizes are derived from rates of physician
screening in the CCSS population [32,56]. Similar in-
creases for self-screening were found in a trial focused on
skin self-examination amongst the siblings of melanoma
patients conducted by Geller and Emmons [50]. Assuming
that baseline physician screening rates are 30% across all
randomization groups, a 10 to 15% increase in physician
screening rates would be considered a clinically significant
improvement. Based on an estimated 25% attrition rate by
month 18, we propose recruiting 801 subjects who will beevenly divided across the 3 intervention groups. Using a
main effects model, the design has at least 80% power to
detect a 15% difference across any of the arms even if one
takes a conservative 0.025 threshold for statistical signifi-
cance. This is based on a 2-degree of freedom chi-squared
test with n = 200 in each arm, assuming the screening rate
in the PAE arm is 30% and at least one of the other arms
is 15% higher. The actual power in this scenario is 85%.
We will use a conservative 0.025 threshold to account for
multiple comparisons.
In the unexpected case that the PAE-alone arm is
found to be superior to the other 2 arms, we will have a
number of mechanisms in place to study this from our
baseline, 12- and 18-month surveys. In particular, we
will be asking many questions on physician screening of
the participants in all three conditions. It could be that
participants are deterred by added involvement of their
physicians, although the literature shows that physician
prompts are some of the greatest influences in increas-
ing screening behaviors. We will also have a series of
questions specific to Arm 3 participants to test if there
has been any part of the addition of the technology com-
ponent that was off-putting (for example, some partici-
pants who are either overwhelmed, do not understand
how to utilize it, or perhaps do not trust the transmis-
sion of their personal health information).
Discussion
Focus on the long-term health outcomes of survivors of
childhood cancer is of vital public health significance, as
their 5-year survival rates now exceed 80%. Survivors
treated with radiation therapy are currently at increased
risk of developing both melanoma and basal cell carcin-
oma; incidence of squamous cell carcinoma may also
emerge as the population ages. In theory, early detection
can save lives and reduce morbidity, in practice though,
screening rates are sub-optimal [32,56]. Less than optimal
screening rates may be driven by lack of awareness of risk
and lack of knowledge of how to conduct skin examina-
tions by patients and physicians alike. The ASK study will
address many of these barriers by providing educational
and motivational information for both survivors and phy-
sicians regarding skin examinations, prompts via text mes-
saging for survivors, and print and online resources for
patients and providers. Equally important, we will attempt
to narrow the interval from first detection of suspected
skin cancer to treatment through the added dimension of
teledermoscopy, which provides highly accurate prelimin-
ary information about the morphology of a lesion and can,
in turn, lead to expedited care if needed.
There are a number of potential limitations, including
recall bias and social desirability bias, specific to one of
the three study conditions. Although it is highly unlikely
that PAE alone or PAE with added interventions would
cause worse outcomes than standard-of-care, because
there is not a control group with no PAE, the study will
not be able to detect such potential outcomes. In
addition, social desirability may incline some participants
to answer questions in a way that they think will be con-
sidered favorable by others. For example, if participants
see that study researchers promote monthly skin self-
checks, some may over report this behavior to appear
more compliant with the expectations and desires of the
researchers. Potentially over reporting positive behavior
and/or under reporting negative behavior could bias the
data and lead to inaccurate conclusions. However, con-
sideration was given to ensure that questions and re-
sponse options were not phrased in a way that would
incline participants to choose a response because they
felt it was ‘correct’. Another possible limitation is that
the study staff will not observe participant performance
of skin self-examination; therefore, the accuracy of these
exams will not be able to be validated. The same is true
regarding the accuracy and thoroughness of physician
skin exam reports although documentation of screening
will be verified through chart review. However, we have
provided numerous resources to instruct and guide both
participants and physicians regarding how to perform
thorough, accurate skin examinations in several me-
diums (for example, written instructions, step-by-step
guides with illustrations, and video tutorials). An add-
itional potential limitation is that physicians may per-
form clinical skin examinations but may not document
them in their patients’ charts, resulting in underreport-
ing of clinical skin exams.
There are many strengths to the current study, par-
ticularly regarding the use of innovative technology and
methods. First, we are targeting the three primary fac-
tors needed to result in reduced risk of serious skin can-
cers: (1) patient skin self-examinations; (2) physician
full-body skin exams; and (3) rapid access to dermatolo-
gist evaluation of worrisome lesions. Second, we are fo-
cusing on both patient activation, a very important but
not previously studied component of increasing skin
cancer early detection, as well as activating patients’ pri-
mary physicians to conduct skin exams while providing
them with the educational information needed to do so
effectively. Third, we are providing a subset of study par-
ticipants with a dermatoscope that easily attaches to a
variety of smartphones or tablets to provide high-quality
photographs of suspect lesions that will maximize the
quality of teledermoscopy and increase access to evalu-
ation. Because this technology is rapidly evolving, it is
likely that the cost of such devices will continue to de-
crease and become increasingly available to the general
population. Finally, this study has been designed as a com-
parative effectiveness trial, which will isolate the effects of
adding specific components to the patient activationintervention. The inclusion of an economic component is
just one reason to call this study a comparative-
effectiveness trial. We strongly considered employing a
true control group that would receive no website educa-
tion or text messages. Upon much reflection though, it
was felt that the inclusion of such activities could be at
once effective, easy to implement, and have a broad reach.
Having such information from patients in the PAE
group aligns with basic principles of comparative effect-
iveness research that is ‘designed to inform health care
decisions to prevent, diagnose and treat health condi-
tions by providing evidence of the effectiveness, benefits,
and harms of various treatment options generated from
research studies comparing multiple ways to deliver health
care’ [57,58], all key features of the current study. In
addition, this study intends to translate and disseminate
research findings to diverse stakeholders at its conclusion
to inform patients, providers, and decision-makers about
which interventions are most effective for patients under
specific circumstances, another key feature of comparative
effectiveness trials [57]. This study represents the first at-
tempt that we are aware of to employ disseminable and
scalable technologies to activate high-risk patients to
examine their skin for cancer, seek physician exams, and
obtain expedited treatment.
It is anticipated that results from this intervention will
have important implications for childhood cancer survi-
vors and other high-risk populations, including organ
transplant recipients (>225,000 recipients) and first-degree
relatives of melanoma patients (>2 million Americans), all
of whom share strong deficits in skin self-examinations
and receipt of physician examinations for skin cancer
[50,59-62].
Trial status
We have not completed patient recruitment at the time
of submission.
Abbreviations
ABCDE: Asymmetry, Border, Color, Diameter, Evolution; ASK: Advancing
Survivors’ Knowledge; BCC: basal cell carcinoma; CCSS: Childhood Cancer
Survivor Study; ED: Early Detection; HCP: Health Care Provider; HIPAA: Health
Insurance Portability and Accountability Act; FU5: Childhood Cancer Survivor
Study Follow-Up 5 survey; LED: light-emitting diode; PAE: Patient Activation
and Education; PAE + MD: Patient Activation and Education plus physician
activation; PAE + MD + TD: Patient Activation and Education plus physician
activation, plus teledermoscopy; PAM: Patient Activation Measure;
RBRVS: Resource Based Relative Value Scale; TSSE: thorough skin self-examination;
US: United States.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ACG, KME, ACM, AAM, and SWD conceived of the study and design. ACG,
RRK, KMS, KME, GTA, and LLR created and edited the study protocol utilized
in this manuscript. EBE developed the cost-benefit analysis measures and
analysis. AJM, RRK, JAD, CLD, and ACG designed the recruitment protocol.
KMS and CC coordinated and led development of intervention materials
Daniel et al. Trials  (2015) 16:109 Page 10 of 11(print and web). SJH designed the statistical analyses and is the Study Biostatistician.
ACG is the Principal Investigator, RRK is the Program Director, JAD is the Project
Manager, and AAM is the Study Dermatologist. CLD, RRK, JAD, and ACG drafted the
manuscript. All authors read and approved the final manuscript.Acknowledgements
This study is funded by NCI grant R01 CA175231 (A Geller, Principal
Investigator, Reducing Skin Cancer Risk among Childhood Cancer Survivors,
2013 to 2018). This work was supported by the National Cancer Institute
(CA55727, GT Armstrong, Principal Investigator). Support to St. Jude
Children’s Research Hospital also provided by the Cancer Center Support
(CORE) grant (CA21765, R Gilbertson, Principal Investigator) and the American
Lebanese-Syrian Associated Charities (ALSAC). The first author is supported
by NCI grant R25 CA057711 (G Sorensen, Principal Investigator). We thank
Dana-Farber/Harvard Cancer Center in Boston, MA for the services of the
Health Communication Core (www.healthcommcore.org), which provided
assistance with planning, writing, designing, and developing the print and
online components of the study materials. Dana-Farber/Harvard Cancer
Center is supported in part by an NCI Cancer Center Support Grant # NIH 5
P30 CA06516.
Author details
1Department of Social and Behavioral Sciences, Harvard TH Chan School of
Public Health, 677 Huntington Avenue, Kresge 718, 02115-6028 Boston, MA,
USA. 2Department of Epidemiology and Cancer Control, St. Jude Children’s
Research Hospital, 262 Danny Thomas Place, MS 735, 38105-3678 Memphis,
TN, USA. 3Department of Medical Oncology, Dana-Farber Cancer Institute,
450 Brookline Ave, LW601, 02215-5450 Boston, MA, USA. 4Department of
Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Avenue,
02215-5450 Boston, MA, USA. 5Department of Biostatistics, Harvard TH Chan
School of Public Health, 655 Huntington Avenue, Bldg 2, Rm 451,
02115-6009 Boston, MA, USA. 6Department of Pediatrics, Emory University,
Emory Children’s Center, 2015 Uppergate Drive, 4th floor, 30322-1014
Atlanta, GA, USA. 7Kaiser Permanente, 1800 Harrison Street, 16th Floor,
#161R03, 94612-3463 Oakland, CA, USA. 8Memorial-Sloan Kettering Cancer
Center, 1275 York Ave, 10065-6007 New York, NY, USA. 9Department of
Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275
York Avenue, Box 44, 10065-6007 New York, NY, USA. 10Department of
Medicine, Memorial Sloan-Kettering Cancer Center, 160 East 53rd St, 2nd
Floor, 10022-5243 New York, NY, USA.
Received: 5 December 2014 Accepted: 5 March 2015References
1. SEER Cancer Statistics Review. 1975–2010. http://seer.cancer.gov/csr/
1975_2010/. Accessed 10 November 2014.
2. Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: life-long
risks and responsibilities. Nat Rev Cancer. 2014;14:61–70.
3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows
AT, et al. Chronic health conditions in adult survivors of childhood cancer.
N Engl J Med. 2006;355:1572–82.
4. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR,
et al. Clinical ascertainment of health outcomes among adults treated for
childhood cancer. JAMA. 2013;309:2371–81.
5. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, et al.
Development of risk-based guidelines for pediatric cancer survivors: the Children’s
Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology
Group Late Effects Committee and Nursing Discipline. J Clin Oncol.
2004;22:4979–90.
6. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI,
et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review
of published findings. J Clin Oncol. 2009;27:2339–55.
7. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure
among adult survivors of childhood cancer: results from the childhood cancer
survivor study. Radiat Res. 2010;174:840–50.
8. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M,
et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the
Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102:1083–95.9. Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, et al.
Long-term risks of subsequent primary neoplasms among survivors of childhood
cancer. JAMA. 2011;305:2311–9.
10. Olsen JH, Moller T, Anderson H, Langmark F, Sankila R, Tryggvadottir L, et al.
Lifelong cancer incidence in 47,697 patients treated for childhood cancer in
the Nordic countries. J Natl Cancer Inst. 2009;101:806–13.
11. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ,
et al. Health-status of adult survivors of childhood cancer: a large-scale
population-based study from the British Childhood Cancer Survivor Study.
Int J Cancer. 2007;121:633–40.
12. Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, et al.
Nonmelanoma skin cancer in survivors of childhood and adolescent cancer:
a report from the childhood cancer survivor study. J Clin Oncol.
2005;23:3733–41.
13. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M,
et al. Second neoplasms in survivors of childhood cancer: findings from
the Childhood Cancer Survivor Study cohort. J Clin Oncol.
2009;27:2356–62.
14. Watt TC, Inskip PD, Stratton K, Smith SA, Kry SF, Sigurdson AJ, et al.
Radiation-related risk of basal cell carcinoma: a report from the Childhood
Cancer Survivor Study. J Natl Cancer Inst. 2012;104:1240–50.
15. Pappo AS, Armstrong GT, Liu W, Srivastava DK, McDonald A, Leisenring WM,
et al. Melanoma as a subsequent neoplasm in adult survivors of childhood
cancer: a report from the childhood cancer survivor study. Pediatr Blood
Cancer. 2013;60:461–6.
16. Mertens ALW, Mitby P, Hammond S, Perkins J, Robison L, Hudson M, et al.
Sun sensitivity, sun exposure and risk of skin cancer in a cohort of adult
survivors of childhood and adolescent cancer. A report from the Childhood
Cancer Survivor Study. In: 10th International Conference on Long-Term
Complications of Treatment of Children & Adolescents for Cancer. 2008.
17. Alam M, Goldberg LH, Silapunt S, Gardner ES, Strom SS, Rademaker AW,
et al. Delayed treatment and continued growth of nonmelanoma skin
cancer. J Am Acad Dermatol. 2011;64:839–48.
18. Kricker A, Armstrong B, Hansen V, Watson A, Singh-Khaira G, Lecathelinais C,
et al. Basal cell carcinoma and squamous cell carcinoma growth rates and
determinants of size in community patients. J Am Acad Dermatol.
2014;70:456–64.
19. Late Effects of Treatment for Childhood Cancer (PDQ®). http://www.cancer.
gov/cancertopics/pdq/treatment/lateeffects/Patient/page2. Accessed 10
November 2014.
20. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent,
and Young Adult Cancers, Version 3.0. http://www.survivorshipguidelines.
org. Accessed 5 November 2014.
21. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early
detection, and trends for melanoma: current status (2000–2006) and future
directions. J Am Acad Dermatol. 2007;57:555–72. quiz 573–556.
22. Weinstock MA, Martin RA, Risica PM, Berwick M, Lasater T, Rakowski W, et al.
Thorough skin examination for the early detection of melanoma. Am J Prev
Med. 1999;17:169–75.
23. Koh HK, Miller DR, Geller AC, Clapp RW, Mercer MB, Lew RA. Who discovers
melanoma? Patterns from a population-based survey. J Am Acad Dermatol.
1992;26:914–9.
24. Mayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education,
and trends for melanoma: current status (2007–2013) and future directions:
Part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic
technology. J Am Acad Dermatol. 2014;71:599. e591–12. quiz 610, 599.e512.
25. Mayer JE, Swetter SM, Fu T, Geller AC. Screening, early detection, education,
and trends for melanoma: current status (2007–2013) and future directions:
Part II. Screening, education, and future directions. J Am Acad Dermatol.
2014;71:611. e611–0. quiz 621–612.
26. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous
melanoma by skin self-examination. J Natl Cancer Inst. 1996;88:17–23.
27. Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin
examination reduces the incidence of thick melanomas. Int J Cancer.
2010;126:450–8.
28. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R,
et al. Does skin cancer screening save lives?: an observational study
comparing trends in melanoma mortality in regions with and without
screening. Cancer. 2012;118:5395–402.
29. SPOT Skin Cancer. http://www.aad.org/spot-skin-cancer. Accessed 10
November 2014.
30. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis:
25 years beyond the ABCDs. CA Cancer J Clin. 2010;60:301–16.
31. Geller AC, O’Riordan DL, Oliveria SA, Valvo S, Teich M, Halpern AC.
Overcoming obstacles to skin cancer examinations and prevention
counseling for high-risk patients: results of a national survey of primary care
physicians. J Am Board Fam Pract. 2004;17:416–23.
32. Nathan PC, Ness KK, Mahoney MC, Li Z, Hudson MM, Ford JS, et al.
Screening and surveillance for second malignant neoplasms in adult
survivors of childhood cancer: a report from the childhood cancer survivor
study. Ann Intern Med. 2010;153:442–51.
33. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM,
et al. Study design and cohort characteristics of the Childhood Cancer
Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol.
2002;38:229–39.
34. Leisenring WM, Mertens AC, Armstrong GT, Stovall MA, Neglia JP, Lanctot
JQ, et al. Pediatric cancer survivorship research: experience of the Childhood
Cancer Survivor Study. J Clin Oncol. 2009;27:2319–27.
35. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS,
et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported
resource for outcome and intervention research. J Clin Oncol.
2009;27:2308–18.
36. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient
Activation Measure (PAM): conceptualizing and measuring activation in
patients and consumers. Health Serv Res. 2004;39:1005–26.
37. Hibbard JH, Greene J. What the evidence shows about patient activation:
better health outcomes and care experiences; fewer data on costs. Health
Aff (Millwood). 2013;32:207–14.
38. Hibbard JH, Mahoney E. Toward a theory of patient and consumer
activation. Patient Educ Couns. 2010;78:377–81.
39. Rask KJ, Ziemer DC, Kohler SA, Hawley JN, Arinde FJ, Barnes CS. Patient
activation is associated with healthy behaviors and ease in managing
diabetes in an indigent population. Diabetes Educ. 2009;35:622–30.
40. Cooper LA, Roter DL, Carson KA, Bone LR, Larson SM, Miller 3rd ER, et al. A
randomized trial to improve patient-centered care and hypertension control
in underserved primary care patients. J Gen Intern Med.
2011;26:1297–304.
41. Holman H, Lorig K. Patient self-management: a key to effectiveness and
efficiency in care of chronic disease. Public Health Rep. 2004;119:239–43.
42. Hibbard JH, Mahoney ER, Stock R, Tusler M. Do increases in patient
activation result in improved self-management behaviors? Health Serv Res.
2007;42:1443–63.
43. Solomon M, Wagner SL, Goes J. Effects of a Web-based intervention for
adults with chronic conditions on patient activation: online randomized
controlled trial. J Med Internet Res. 2012;14:e32.
44. Alexander JA, Hearld LR, Mittler JN, Harvey J. Patient-physician role relationships
and patient activation among individuals with chronic illness. Health Serv Res.
2012;47:1201–23.
45. Landow SM, Mateus A, Korgavkar K, Nightingale D, Weinstock MA.
Teledermatology: key factors associated with reducing face-to-face dermatology
visits. J Am Acad Dermatol. 2014;71:570–6.
46. Shaikh WR, Geller A, Alexander G, Asgari MM, Chanange GJ, Dusza S, et al.
Developing an interactive web-based learning program on skin cancer: the
learning experiences of clinical educators. J Cancer Educ. 2012;27:709–16.
47. Weinstock MA. Reducing death from melanoma and standards of evidence.
J Invest Dermatol. 2012;132:1311–2.
48. Weinstock MA, Risica PM, Martin RA, Rakowski W, Smith KJ, Berwick M, et al.
Reliability of assessment and circumstances of performance of thorough
skin self-examination for the early detection of melanoma in the Check-It-Out
Project. Prev Med. 2004;38:761–5.
49. Tsang MW, Resneck Jr JS. Even patients with changing moles face long
dermatology appointment wait-times: a study of simulated patient calls to
dermatologists. J Am Acad Dermatol. 2006;55:54–8.
50. Geller AC, Emmons KM, Brooks DR, Powers C, Zhang Z, Koh HK, et al. A
randomized trial to improve early detection and prevention practices
among siblings of melanoma patients. Cancer. 2006;107:806–14.
51. Rodrigue JR. Promoting healthier behaviors, attitudes, and beliefs toward
sun exposure in parents of young children. J Consult Clin Psychol.
1996;64:1431–6.
52. Manne S, Lessin S. Prevalence and correlates of sun protection and skin
self-examination practices among cutaneous malignant melanoma survivors.
J Behav Med. 2006;29:419–34.53. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of
a short form of the patient activation measure. Health Serv Res.
2005;40:1918–30.
54. Drummond MFSM, Torrance GW, O’Brien B, Stoddart GL. Methods for the
economic evaluation of health care programmes. 3rd ed. New York: Oxford
University Press; 2005.
55. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health
and medicine. New York: Oxford University Press; 1996.
56. Buchanan N, Leisenring W, Mitby PA, Meadows AT, Robison LL, Hudson
MM, et al. Behaviors associated with ultraviolet radiation exposure in a
cohort of adult survivors of childhood and adolescent cancer: a report from
the Childhood Cancer Survivor Study. Cancer. 2009;115:4374–84.
57. Comparative Effectiveness Research (CER). http://www.nlm.nih.gov/hsrinfo/
cer.html. Accessed 20 February 2015.
58. What Is Comparative Effectiveness Research?. http://effectivehealthcare.ahrq.
gov/index.cfm/what-is-comparative-effectiveness-research1/. Accessed 20
February 2015.
59. Robinson JK, Alam M, Ashourian N, Khan M, Kundu R, Laumann AE, et al.
Skin cancer prevention education for kidney transplant recipients: a
systematic evaluation of Internet sites. Prog Transplant. 2010;20:344–9.
60. Feuerstein I, Geller AC. Skin cancer education in transplant recipients. Prog
Transplant. 2008;18:232–41. quiz 242.
61. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ.
Increased incidence of melanoma in renal transplantation recipients. Cancer.
2005;104:1962–7.
62. Singh MK, Brewer JD. Current approaches to skin cancer management in
organ transplant recipients. Semin Cutan Med Surg. 2011;30:35–47.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
